title: Long term phenobarbital administration does not promote the multiplication of hepatocytes replicating after single cyproterone acetate administration.
abstract: Cyproterone acetate (CPA) is a synthetic antiandrogenic compound which is widely used in clinic but suspected to be hepatocarcinogenic. CPA is also mitogenic in rat liver. Using genetic labeling of dividing cells, we examined whether hepatocytes dividing in response to acute CPA administration could give rise to preneoplastic foci after administration of a tumor promoter: phenobarbital. CPA was administered orally to rats and dividing hepatocytes were genetically labeled using retroviral vectors carrying the beta-galactosidase gene. After labeling rats were given phenobarbital for 10 months and sacrificed. The presence of beta-galactosidase labeled hepatocytes as well as preneoplastic hepatocytes was assessed by immunohistochemistry. Genetic labeling of hepatocytes was obtained in all animals. At the end of phenobarbital administration, no hepatic tumors were observed. Preneoplastic foci were not increased in treated animals as compared to control rats. Moreover beta-galactosidase positive hepatocytes were never detected in preneoplastic foci. Finally, the size of the beta-galactosidase positive clusters was smaller in treated animals as compared to control rats. We conclude that acute CPA administration is not carcinogenic in rat liver and does not initiate preneoplastic hepatocytes capable to give rise to foci after phenobarbital promotion. Therefore the mitogenic property of CPA is distinct from its putative carcinogenic activity. Finally, analysis of the size of beta-galactosidase positive cells clusters demonstrate that phenobarbital does not induce hepatocyte proliferation in rats.
authors.affiliation: Biotherapies Hépatiques CIC-INSERM 04, CHU Hotel-Dieu 44035, Nantes, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Pichard
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ferry
mesh_terms: D000726:Androgen Antagonists / Q000633:toxicity*; D000818:Animals; D030801:Animals, Genetically Modified; D002273:Carcinogens / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects*; D017373:Cyproterone Acetate / Q000633:toxicity*; D022781:Hepatocytes / Q000187:drug effects* / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000201:enzymology; D010634:Phenobarbital / Q000494:pharmacology*; D011230:Precancerous Conditions / Q000139:chemically induced / Q000201:enzymology; D051381:Rats; D017207:Rats, Sprague-Dawley; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D000726:Androgen Antagonists; D002273:Carcinogens; D017373:Cyproterone Acetate; D001616:beta-Galactosidase; D010634:Phenobarbital